Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer relapsing on standard dose alectinib

Journal of Thoracic Oncology

Volumn 11, Issue 2, 2016, Pages 256-260

  Gainor, Justin F ^a   Chi, Andrew S ^a   Logan, Jennifer ^a   Hu, Ranliang ^a   Oh, Kevin S ^a   Brastianos, Priscilla K ^a   Shih, Helen A ^a   Shaw, Alice T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alectinib; ALK; Anaplastic lymphoma kinase; Leptomeningeal metastases

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; ANTICONVULSIVE AGENT; CARBOPLATIN; CERITINIB; CORTICOSTEROID; CRIZOTINIB; PEMETREXED; CARBAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADULT; AMNESIA; ANAPLASTIC LYMPHOMA KINASE POSITIVE NON SMALL CELL LUNG CANCER; APHASIA; ARTICLE; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CARCINOMATOUS MENINGITIS; CASE REPORT; CONFUSION; CONSTIPATION; CRANIOTOMY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPEPSIA; EPILEPTIC STATE; FATIGUE; GAIT DISORDER; HEADACHE; HUMAN; HYPOPHOSPHATEMIA; MALE; MIDDLE AGED; NEUROIMAGING; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SEIZURE; SHORT TERM MEMORY; STEREOTACTIC RADIOSURGERY; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; ENZYMOLOGY; LUNG NEOPLASMS; SECONDARY;

ADULT; BRAIN NEOPLASMS; CARBAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84958956983     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2015.10.010     Document Type: Article

References (19)

1. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167-2177.
2. Costa DB, Shaw AT, Ou SH, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol. 2015;33:1881-1888.
3. Ou S-HI, Ahn JS, De Petris L, et al. Efficacy and safety of the ALK inhibitor alectinib in ALK non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-Arm, global phase 2 study (NP28673). J Clin Oncol. 2015;22(suppl):8008 [abstract].
4. Kim D-W, Mehra R, Tan DS, et al. Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK) non-small cell lung cancer (NSCLC): results of the ASCEND-1 trial. J Clin Oncol. 2014;32(suppl):8003 [abstract].
5. Gainor JF, Ou SH, Logan J, Borges LF, Shaw AT. The central nervous system as a sanctuary site in ALKpositive non-small-cell lung cancer. J Thorac Oncol. 2013;8:1570-1573.
6. Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALKrearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014;15:1119-1128.
7. Gainor JF, Sherman CA, Willoughby K, et al. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol. 2015;10:232-236.
8. Ou SH, Sommers KR, Azada MC, Garon EB. Alectinib induces a durable (15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist. 2015;20:224-226.
9. Lee SJ, Lee JI, Nam DH, et al. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol. 2013;8:185-191.
10. Jabbour E, Kantarjian HM, Jones D, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood. 2009;113:2154-2160.
11. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer. 2005;41:1751-1757.
12. Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol. 2010;99:283-286.
13. Grommes C, Oxnard GR, Kris MG, et al. "Pulsatile" highdose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 2011;13:1364-1369.
14. Yu H, Sima C, Reales D, et al. A phase I study of twice weekly pulse dose and daily low dose erlotinib as initial treatment for patients (pts) with EGFR-mutant lung cancers. J Clin Oncol. 2015;33(suppl):8017 [abstract].
15. Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, Sakamoto H. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol. 2014;74: 1023-1028.
16. Katayama R, Friboulet L, Koike S, et al. Two novel ALK mutations mediate acquired resistance to the nextgeneration ALK inhibitor alectinib. Clin Cancer Res. 2014;20:5686-5696.
17. Ignatius Ou SH, Azada M, Hsiang DJ, et al. Nextgeneration sequencing reveals a novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol. 2014;9: 549-553.
18. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20:548-554.
19. Wang Y, Springer S, Zhang M, et al. Detection of tumorderived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci U S A. 2015;112:9704-9709.